

October 1, 2022

UPDATE TO THE MEDSTAR FAMILY CHOICE DISTRICT OF COLUMBIA FORMULARY

MedStar Family Choice District of Columbia (MFC-DC) has a Pharmacy and Therapeutics Committee that meets quarterly. During our August 2022 meeting, formulary changes were made as listed below for DC Healthy Families and DC Healthcare Alliance.

THESE CHANGES BECOME EFFECTIVE OCTOBER 1, 2022 (UNLESS INDICATED OTHERWISE).

Additions:

- NONE

Additions with Prior Authorization Requirement: *

- **CAMZYOS** (mavacamten) - Cardiac myosin inhibitor for cardiomyopathy
- **VIJOICE** (alpelisib) - treatment for PIK3CA

*Please see the PA Table on the MFC-DC website for details of the requirements for approval and guidance on the submission of clinical information.

Removals:

- NONE

Removal of Prior Authorization Requirement:

- **Restasis** (cyclosporine, emulsion) - treatment for dry eyes

Managed Drug Limitations & Step Therapy**

- **Xiidra** (lifitegrast) - treatment for dry eyes

Drug Formulary updates are also available on the MFC-DC Website at MedStarFamilyChoiceDC.com/providers/pharmacy.

*Details of the Prior Authorization Criteria are on the website in the Prior Authorization Table.

**Details of the Step Therapy Criteria are on the website in the Step Therapy Table.

**It's how we
treat people.**